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Abstract
AIM
To study the counteraction of perforated cecum lesion 
using BPC 157 and nitric oxide (NO) system agents.
METHODS
Alongside with the agents’ application (after 1 min, 
medication (/kg, 10 ml/2 min bath/rat) includes: BPC 
157 (10 μg), L-NAME (5 mg), L-arginine (100mg) alone 
or combined, and saline baths (controls)) on the rat 
perforate cecum injury, we continuously assessed the 
gross reappearance of the vessels (USB microcamera) 
quickly propagating toward the defect at the cecum 
surface, defect contraction, bleeding attenuation, MDA- 
5462 December 28, 2018|Volume 24|Issue 48|WJG|https://www.wjgnet.com
ORIGINAL ARTICLE
Counteraction of perforated cecum lesions in rats: Effects 
of pentadecapeptide BPC 157, L-NAME and L-arginine
Basic Study
Domagoj Drmic, Mariam Samara, Tinka Vidovic, Dominik Malekinusic, Marko Antunovic, Borna Vrdoljak, 
Jelena Ruzman, Marija Milkovic Perisa, Katarina Horvat Pavlov, Jerusha Jeyakumar, Sven Seiwerth, 
Predrag Sikiric
Submit a Manuscript: https://www.f6publishing.com
DOI: 10.3748/wjg.v24.i48.5462
World J Gastroenterol  2018 December 28; 24(48): 5462-5476
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
and NO-levels in cecum tissue at 15 min, and severity of 
cecum lesions and adhesions at 1 and 7 d. 
RESULTS
Post-injury, during/after a saline bath, the number of ves-
sels was significantly reduced, the defect was slightly nar-
rowed, bleeding was significant and MDA-levels increased 
and NO-levels decreased. BPC 157 bath: the vessel 
presentation was markedly increased, the defect was no-
ticeably narrowed, the bleeding time was shortened and 
MDA- and NO-levels remained normal. L-NAME: reduced 
vessel presentation but not more than the control, did 
not change defect and shortened bleeding. L-arginine: 
exhibited less vessel reduction, did not change the de-
fect and prolonged bleeding. In combination, mutual 
counteraction occurred (L-NAME + L-arginine) or the pre-
sentation was similar to that of BPC 157 rats (BPC 157 
+ L-NAME; BPC 157 + L-arginine; BPC 157 + L-NAME + 
L-arginine), except the defect did not change. Thereby 
at day 1 and 7, saline, L-NAME, L-arginine and L-NAME + 
L-arginine failed (defect was still open and large adhesions 
present). 
CONCLUSION
The therapeutic effect was achieved with BPC 157 alone 
or in combination with L-NAME and L-arginine as it was 
able to consolidate the stimulating and inhibiting effects of 
the NO-system towards more effective healing recruiting 
vessels.
Key words: BPC 157; Perforated cecum; L-arginine; 
L-NAME; Vessels; Rats
© The Author(s) 2018. Published by Baishideng Publishing 
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Core tip: In rats, the cecum was exposed, and a perfo-
ration (5-mm diameter) was made at the ventral face 
of the basal region of the cecum close to the largest 
curvature. After 1 min, a bath (1 ml/rat) containing BPC 
157, L-NAME, L-arginine, saline (controls) was directly 
applied to the perforated cecum, alone or in combination. 
Previously, BPC 157 rapidly activated the collateral 
circulation from existing vessels in ischemic colitis or 
inferior caval vein occlusion (by passing through the 
arcade vessels or the left ovarian vein and other veins) to 
reestablish blood flow and exert its free radical scavenger 
effect in both ischemia and reperfusion. 
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INTRODUCTION
In cecum perforation studies[1-3] the immediate post-
perforation threat is rarely studied, particularly regarding: 
the rapid disappearance of blood vessels in the cecum 
serosa that are instantly emptied and thereby “disappear”, 
perforation defect enlargement, bleeding and fluid 
leakage, increased oxidative stress and disturbed nitric 
oxide (NO) levels in cecum tissue. Likewise, the possible 
effect of cytoprotective agents, known to act as a class 
on endothelium maintenance in the gastrointestinal tract 
(and, thereby, mucosal maintenance)[4-9], especially the 
stable gastric pentadecapeptide BPC 157 as a cytopro-
tective agent rapidly acting on endothelium integrity 
maintenance[10-19], has been not investigated. 
We focused on a perforated cecum, the stable gastric 
pentadecapeptide BPC 157, the NOS-blocker L-NAME, 
and the NOS-substrate L-arginine, as well as on the initial 
post-perforation period, rapid disappearance of blood 
vessels at the cecum serosa (emptied/disappeared), 
a large immediate defect, bleeding, leakage of fluid, 
increased oxidative stress and disturbed NO levels in 
cecum tissue. The rationale was the beneficial effects in 
rats with ischemic colitis and inferior caval vein occlusion 
syndrome[20,21] and the particular effect of BPC 157 on 
blood vessels[20,21]. Namely, we recently demonstrated 
that BPC 157 rapidly activated the collateral circulation 
from existing vessels in rats with ischemic colitis or 
inferior caval vein occlusion[20,21]. In ischemic colitis (i.e., 
segment of the left colic artery and vein excluded by two 
ligations) we proved effectiveness by passing through 
arcade vessels[20]. Antagonizing the syndrome of inferior 
caval vein infrarenal occlusion, we evidenced by passing 
through the left ovarian vein and other veins[21]. These 
accentuated the specific action of BPC 157 to reestablish 
blood flow, and exert its free radical scavenger effect in 
both ischemia and reperfusion[20,21]. 
In addition, BPC 157, as a novel mediator of Robert’s 
cytoprotection[4,10-19], also affects several other molecular 
pathways[21-27]. It is native and stable in human gastric 
juice and maintains gastrointestinal mucosal integ-
rity[10-19], and it represents a prototype of a more effective 
class of cytoprotective agents with both prophylactic and 
therapeutic abilities[5,17] (unlike standard cytoprotective 
agents that exhibit only prophylactic effectiveness 
(shared limitation of activity))[4-9]. BPC 157 (used in ulce-
rative colitis and now in multiple sclerosis trials) also 
counteracts colitis (in various models of colitis)[20,28-33] 
and its complications, such as fistulas[34-38], failed healing 
of anastomoses[28,29,39,40] and other gastrointestinal le-
sions[10-19], given parenterally or orally. Furthermore, BPC 
157 is known to counteract thrombosis, not only after 
abdominal aorta anastomosis[41] or inferior caval vein 
ligation[21], but also after bleeding prolongation upon 
amputation and the administration of anticoagulants 
and aspirin[42,43] or inferior caval vein ligation[21]. This 
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effect is related to its endothelial maintenance[21,41-43] 
and its interaction with the NO system, which provides 
the counteraction of both the opposite effects of L-NAME 
(prothrombotic) and L-arginine (antithrombotic) appli-
cation[43]. Otherwise, bleeding from the perforated lesion 
and perforated lesion outcome might be complicated 
with these innate L-NAME and NOS substrate L-arginine 
effects[43]. 
In practice, as described previously[20,21], our ap-
proach to cure a perforated cecum begins with the 
original understanding of stomach cytoprotection (a 
very rapid protection of the stomach endothelium and 
epithelium against diverse direct injuries; endothelium 
maintenance → epithelium maintenance), regularly 
shown with cytoprotective agents[4-9]. This was further 
perceived as an extended cytoprotection background[20,21] 
(endothelium maintenance → epithelium maintenance 
= blood vessel recruitment and activation towards the 
site of injury), also described as “bypassing” occlusion 
via alternative ways, as demonstrated with BPC 157[20,21], 
which can likely cure rats with a perforated cecum and 
thereafter. Furthermore, antagonization of two distinct 
detrimental obstructive events (i.e., left colic artery and 
vein ligation-colitis and inferior caval vein-infrarenal 
ligation-full syndrome)[20,21] appears. Likewise, positive 
outcome matching also appears, providing a special ef-
fect: blood vessel recruitment to organize bypassing of 
vessel occlusions and reestablishment of blood flow by 
BPC 157 therapy[20,21]. Thus, we can make the argument 
that, under analogous or more severe conditions (i.e., 
perforated cecum), a similar positive outcome will appear. 
If this occurs, we can attenuate cecum perforation 
syndrome; in BPC 157-treated rats, therapy may lead 
to attenuation and reversal of the consequent tissue 
damage. Specifically, a reversal of vessel disappearance 
by vessels “running” toward the defect (vessels filled/
reappeared), transition of defect enlargement to defect 
narrowing (note, fistula defects healing)[34-38], change 
from prolonged bleeding to bleeding attenuation[21,42,43], 
induced reduction of increased MDA values and nor-
malization of NO values in cecum tissue[20,21]. In sub-
sequent days and weeks, this may lead to a closed ce-
cum defect and attenuation of adhesion formation.  
For further clarification and to demonstrate a direct 
beneficial effect, medication (BPC 157, L-NAME, and 
L-arginine, alone and/or together) was applied directly 
to the injury[20,21] once during surgery, as a bath to the 
perforated cecum, the solution then spread throughout 
the abdominal cavity. Consequently, the beneficial effects 
are directly related to the reversal of perforated injury 
outcome consequences, in both the early and later pe-
riods. These effects may be triggered shortly after injury 
initiation, or reverse an already advanced injury course.
MATERIALS AND METHODS
Animals
Male Albino Wistar rats, 200 g b.w., were randomly 
assigned (7 rats per group) and used for the experi-
ments, which were approved by the local ethics com-
mittee. The perforation procedure was performed in rats 
that had food and water ad libitum before the procedure 
and until the end of the experiment. 
Drugs
Pentadecapeptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-
Asp-Asp-Ala-Gly-Leu-Val, M.W. 1419, named BPC 157, 
a part of the sequence of human gastric juice protein 
encoded by BPC, freely soluble in water at pH 7.0 and 
in saline, was prepared (Diagen, Ljubljana, Slovenia) as 
described previously[10-21]. The peptide with 99% high-
pressure liquid chromatography (HPLC) purity, 1-des-Gly 
peptide as a biologically inactive impurity, was used[10-21]. 
L-NAME and L-arginine were commercially purchased 
(Sigma, United States).
Perforated defect creation, medication, assessment
In deeply anaesthetized rats (thiopental (Rotexmedica, 
Germany) 40 mg/kg ip, apaurin (Krka, Slovenia) 10 mg/
kg ip), the cecum was exposed, and a perforation (5-mm 
diameter) was made at the ventral aspect of the basal 
region of the cecum close to the largest curvature; the 
rats were monitored for the next 15 min. 
After 1 min, a bath (1 mL/rat) containing BPC 157 
(0.01 mg/kg), NOS blocker L-NAME (5 mg/kg), or NOS 
substrate L-arginine (100 mg/kg) was directly applied 
to the perforated cecum, alone or combined, and sp-
read through the abdominal cavity, whereas controls 
accordingly received a saline bath of equal volume. 
Using a USB microscope camera (Veho discovery 
VMS-004D-400x USB microscope; Veho®, United 
Kingdom), from the point immediately before therapy, 
we recorded and assessed the blood vessels (emptied/
disappeared; refilled/reappeared) (total % of cecum 
vessel augmentation/reduction from proximal to distal 
end = [number of blood vessels (10 vessels assessed) 
/100] × %] in terms of augmentation/reduction of each 
vasa recta (0 as the point immediately before therapy) 
and defect closing or widening (as % of presentation 
immediately before therapy) and at particular time 
points: A-after perforation (1 min), B-during application 
(2 min), C-period after application (2 min), D-next 5 
min period and E-period until the end of observation (15 
min). The bleeding time (s) throughout that period was 
also assessed; at 15 min, oxidative stress was measured 
by quantifying thiobarbituric acid (TBA) reactivity as 
malondialdehyde (MDA) equivalents, and nitric oxide 
determination in cecum tissue was also carried out. 
At day 1 and day 7, rats were relaparotimiezed, 
and we assessed the serosal/mucosal defect (longest 
lesion diameter, mm) and adhesion severity scoring 
(adhesions of the abdominal wall-1 point; adhesions of 
the intestine-1 point; adhesions of the cecal area: ventral 
side-1 point/dorsal side-1 point; adhesions involving 
both the intestine and colon-3 points) (resulting in a total 
maximum score of 7). Representative tissue sections 
were processed for further histological analysis as de-
scribed previously[10-21]. 
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(Figure 4), MDA-cecum level (Figure 5); and final course 
of the injury: cecum defect and adhesions at 1 or 7 days 
(Table 1)] are significant in several respects. 
Depending on the agent applied, the initial defensive 
response confers blood vessel presentation (emptied/
disappeared; refilled/reappeared) and augmentation/
reduction (Figures 1, 6 and 7), defect closing or widening 
(Figure 2) and bleeding prolongation or shortening 
(Figures 3 and 7). MDA oxidative stress (Figure 5) and 
NO levels (Figure 4) were determined in the cecum 
tissue as well. They permit combining of initial response 
to the final response (cecum defect and adhesions at 1 
or 7 days (Table 1)].
Initial course, blood vessel presentation, bleeding, and 
defect contraction 
Controls: In rats that received a saline bath, the initial 
course was progressive vessel disappearance and very 
poor vessel branching, which occurred during application 
(Figures 1 and 6). Thereafter, the defect only had a 
small initial contraction (Figure 2) and then continuous 
widening. Additionally, there was a significant bleeding 
period (Figures 3 and 7).
BPC 157 therapy: Rats with a perforated cecum that 
underwent a BPC 157 bath exhibited progressive vessel 
presentation toward the injury (i.e., a network of small 
vessels branching around the injury) (Figures 1 and 6). 
The defect contracted during application (Figure 2) and 
the bleeding period was significantly shortened thereafter 
(Figure 3). 
L-arginine therapy: After application of L-arginine, 
rats with a perforated cecum exhibited less vessel disap-
pearance (Figure 1). We noted counteracted defect wide-
ning (Figure 2), and the bleeding period was significantly 
prolonged (Figure 3).
L-NAME therapy: After application of L-NAME, rats 
with a perforated cecum exhibited vessel disappearance 
similar to controls (Figure 1). There was counteraction of 
defect widening (Figure 2), and the bleeding period was 
shortened (Figure 3).
Combination therapy of L-arginine and L-NAME: 
After application of L-arginine and L-NAME, rats with a 
perforated cecum exhibited a combined effect, with less 
vessel disappearance (Figure 1), counteracted defect 
widening (Figure 2) and a bleeding period in the range of 
that for the control animals (Figure 3).
Combined therapy of L-arginine and/or L-NAME 
with BPC 157: After application of BPC 157 with 
L-arginine and/or L-NAME, rats with a perforated cecum 
that underwent combined BPC 157 therapy (L-NAME + 
BPC 157; L-arginine + BPC 157; L-NAME + L-arginine + 
BPC 157) regularly exhibited progressive vessel presen-
tation (Figure 1) and a shortened bleeding time (Figure 3), 
Oxidative stress in cecum tissue
At 15 min post-injury, oxidative stress in the tissue 
samples (1 cm2 around the defect) was assessed by 
quantifying thiobarbituric acid (TBA) reactivity as malon-
dialdehyde (MDA) equivalents. Trichloroacetic acid (TCA) 
was added to homogenize the tissue samples, which 
were then centrifuged (3000 rpm, 5 min), and the super-
natant was collected. Thereafter, 1% TBA was added, 
and the samples were boiled (95 ℃, 60 min). The tubes 
were kept on ice for 10 min, and the absorbance was 
determined at the wavelengths of 532 and 570 nm. 
The concentration of MDA was read from a standard cali-
bration curve plotted using 1,1,3,3’-tetra-ethoxy propane 
(TEP). The extent of lipid peroxidation was expressed as 
MDA using a molar extinction coefficient for MDA of 1.56 
× 105 mol/(L•cm). The results are expressed in nmol/mg 
of protein[20,21].
Nitric oxide determination in cecum tissue
At 15 min post-injury, we determined the nitric oxide (NO) 
levels in cecum tissue samples using the Griess reaction 
(Griess Reagent System, Promega, United States). Sul-
fanilamide was then incubated with the homogenized 
tissue, and then, N-1-naphthylethylenediamine dihydro-
chloride was added. The Griess reaction is based on a 
diazotization reaction in which acidified nitrite reacts with 
diazonium ions and, in a further step, are coupled to 
N-1-naphthylethylenediamine dihydrochloride, forming 
a chromophoric azo derivate. The absorbance was mea-
sured at 540 nm using sodium nitrite solution as the 
standard. NO levels are reported in μmol/mg protein. 
The protein concentrations were determined using a com-
mercial kit (BioRad Protein DR Assay Reagent Kit, United 
States)[20,21].
Statistical analysis 
Statistical analysis was performed by parametric one-
way ANOVA with the post-hoc Newman-Keuls test and 
non-parametric Kruskal-Wallis and subsequent Mann-
Whitney U-tests to compare the groups. The values are 
represented as means ± SD and minimum/median/ma-
ximum. The results with P < 0.05 were considered sig-
nificant. 
RESULTS
After direct administration of the agents to the site of 
injury one minute after cecum perforation, the results 
obtained can clearly describe the ongoing events. Of 
note, after the administration of the drug directly to the 
lesion, the solution spread through the abdominal cavity; 
however, its effect can still be directly correlated with the 
injury course (aggravated, regular, reversed), particularly 
in the earliest period, and then, the final outcome is seen 
at one week after surgery and medication application.
The numerous negative changes [i.e., initial course: 
vessel presentation (Figure 1), defect closing or widening 
(Figure 2), bleeding time (Figure 3), NO-cecum level 
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Total % of cecum vessels augmentation/reduction from proximal to distal end, means ± SD 
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Figure 1  Blood vessels, filled/appearance or cleared out/disappearance (assessed with a USB microscope camera, Veho discovery VMS-004D-400x USB 
microscope), as [total % of cecum vessels augmentation/reduction from proximal to distal end = [number of blood vessels (10 vessels assessed) /100] x 
% of augmentation/reducing of each vasa recta (0 as point immediately before therapy) (A)]. A: after perforation (1 min); B: during application (2 min); C: the 
period after application (2 min); D: the subsequent 5-min period; E: the period until the end of the observation (15 min). At 1 min post-injury, medication (/kg, 10 mL/2 
min bath/rat) administered at the perforated (5 mm diameter) cecum lesion and cecum (M-mucosa; S-serosa), including BPC 157 (10 μg), NOS blocker L-NAME (5 
mg), NOS substrate L-arginine (100 mg) alone or combined, and saline bath of equal volume (controls). Rats were then left after abdominal closure undisturbed until 
sacrifice, at day 1 or day 7. aP < 0.05 vs control.
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Defect closing or widening as % of defect presentation immediately before therapy (A), means ± SD
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Figure 2  Defect closing or widening [both as % of presentation immediately before therapy (A)]; bleeding time (s); A: after perforation (1 min); B: during 
application (2 min); C: the period after application (2 min); D: the subsequent 5-min period; E: the period until the end of the observation (15 min). At 1 min 
post-injury, administration of medication (/kg, 10 mL/2 min bath/rat) at the perforated (5 mm diameter) cecum lesion and cecum (M-mucosa; S-serosa), including BPC 
157 (10 μg), NOS blocker L-NAME (5 mg), NOS substrate L-arginine (100 mg) alone or combined, and a saline bath equal volume (controls). Rats were then left after 
abdominal closure undisturbed until sacrifice, at day 1 or day 7. aP < 0.05 at least vs control.
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similar to the rats that received BPC 157 alone. All rats 
exhibited counteraction of defect widening (Figure 2).
Final course, defect and adhesion presentation at one 
day and one week of follow up
Controls: Regularly, after one day or one week, rats 
that underwent cecum perforation presented with a 
significant defect (Table 1, Figure 8) that remained open 
and showed significant adhesions (Table 1).
BPC 157 therapy: Rats with a perforated cecum that 
underwent a BPC 157 bath exhibited an attenuated 
defect and finally, no gross defect (Table 1, Figure 8), and 
markedly fewer adhesions were present. 
L-arginine therapy: Rats with a perforated cecum that 
underwent an L-arginine bath initially exhibited an open 
defect larger than in the controls, and markedly more 
adhesions were present (Table 1).
L-NAME therapy: Rats with a perforated cecum that 
underwent an L-NAME bath exhibited an open defect 
larger than that in the controls, and markedly more ad-
hesions were present (Table 1).
Combined therapy of L-arginine and L-NAME: Rats 
with a perforated cecum that underwent this combined 
therapy exhibited an open defect that was found to be 
larger than that in the controls, and markedly more ad-
hesions were present (Table 1).
Combined therapy of L-arginine and/or L-NAME 
with BPC 157: BPC 157 with L-arginine and/or L-NAME 
(L-NAME+BPC 157; L-arginine+BPC 157; L-NAME+L-
arginine+BPC 157) led to defect attenuation and even-
tually no defect grossly present with fewer adhesions, 
similar to the rats that received BPC 157 alone (Table 1). 
NO level
In the early term, NO level assessment demonstrated 
a reduction in the levels in rats that underwent cecum 
perforation, but the NO values in rats with a perforated 
cecum that underwent BPC 157 medication were similar 
to those in healthy rats (Figure 4).
Lipid peroxidation
In the early stages, lipid peroxidation assessment 
demonstrated a huge increase in rats that underwent 
cecum perforation but no MDA oxidative stress in rats 
with a perforate cecum that underwent BPC 157 medi-
cation (Figure 5).
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Figure 3  Bleeding time after perforation. At 1 min post-injury, administration 
of medication (/kg, 10 mL/2 min bath/rat) at the perforated (5 mm diameter) 
cecum lesion and cecum includes BPC 157 (10 μg) (B), NOS blocker L-NAME 
(5 mg) (N), NOS substrate L-arginine (100 mg) (A) alone or combined, and a 
saline bath of equal volume (controls) (S). Rats were then left after abdominal 
closure undisturbed until sacrifice, at day 1 or day 7. aP < 0.05 at least vs 
control (S).
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Figure 5  At 15 min post-injury, oxidative stress in tissue samples was 
assessed by quantifying thiobarbituric acid reactivity as malondialdehyde 
equivalents. Administration of medication (/kg, 10 mL/2 min bath/rat) at the 
perforated (5 mm diameter) cecum lesion and cecum was BPC 157 (10 μg) or 
a saline bath of equal volume (controls). Minimum aP < 0.05 vs control. MDA: 
Malondialdehyde equivalents.
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Figure 4  15 min post-injury, we determined nitric oxide in cecum tissue 
samples using the Griess reaction. Administration of medication (/kg, 10 
mL/2 min bath/rat) at the perforated (5 mm diameter) cecum lesion and 
cecum was BPC 157 (10 μg) or a saline bath equal volume (controls). 
Minimum aP < 0.05 vs control.
Control Perforated cecum, 15 min
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Microscopy
At the first day post-injury, controls exhibited intensive 
edema, loss of glands in the vicinity of the perforation, 
scarce inflammation, and neutrophils. By contrast, BPC 
157-treated animals had much less edema, intensive 
inflammation (mixed neutro and mono) and a fibrin cloth 
attached to the defect (‘holding’ the edges) (Figure 9). 
In control animals, after 7 d, the perforation showed 
c
Before
therapy
With
therapy
C
b
Before
therapy
B
With
therapy
Figure 6  The perforated cecum. Perforate lesions, before therapy (c, b) (left). Perforate lesions with therapy [control, saline (C), BPC 157 (B)] (right). Illustrative 
distinctive effect of medication administration (saline bath (right, upper, control (C) vs BPC 157 bath [right, low, BPC 157 (B)]. Regular failing effect of saline bath 
application on vessels presentation [right, upper, control (C)] vs the immediate recruitment effect of BPC 157 bath administration on the blood vessels presentation 
toward the perforated injury [right, low, BPC 157 (B)]. Note the initial recovery of blood vessels that appear alongside with the BPC 157 bath, a network raising toward 
the perforated defect.
Medication (/kg, 10 ml/2 min bath/rat) Assessed cecum lesion (sum of longest diameters, mm, means ± SD) and adhesion severity (score 
0-9, Min/Med/Max)
Day 1 Day 7
Perforated cecum lesion Adhesion severity Perforated cecum lesion Adhesion severity
0.9%NaCl (control) 5.0 ± 0.5 (M) 3/3/3 5.0 ± 0.5 (M) 3/4/4
5.0 ± 0.5 (S) 6.0 ± 0.5 (S)
BPC 157 (10 µg) 3.0 ± 0.0 (M)a 1/1/1a 0.0 ± 0.0 (M)a 1/1/2a
3.0 ± 0.0 (S)a 0.0 ± 0.0 (S)a
L-NAME 5 mg 7.5 ± 0.4 (M)a 5/6/6a 8.0 ± 0.4 (M)a 6/6/6a
7.5 ± 0.5 (S)a 8.8 ± 0.5 (S)a
L-arginine 100 mg 7.0 ± 0.0 (M)a 4/5/5a 7.5 ± 0.3 (M)a 5/6/6a
7.0 ± 0.0 (S) 8.0 ± 0.4 (S)a
L-NAME 5 mg + 7.3 ± 0.5 (M) 5/6/6a 8.0 ± 0.3 (M) 5/6/6a
L-arginine 100 mg 7.3 ± 0.5 (S) 8.2 ± 0.5 (S)
L-NAME 5 mg + BPC 157 10 μg 3.0 ± 0.0 (M)a 1/1/1a 0.0 ± 0.0 (M)a 1/1/2a
3.0 ± 0.0 (S)a 0.0 ± 0.0 (S)a
L-arginine 100 mg + BPC 157 10 μg 3.0 ± 0.0 (M)a 1/1/1a 0.0 ± 0.0 (M)a 1/1/2a
3.0 ± 0.0 (S)a 0.0 ± 0.0 (S)a
L-NAME 5 mg + L-arginine 100 mg + BPC 157 10 μg 3.0 ± 0.0 (M)a 0/1/1a 0.0 ± 0.0 (M)a 1/1/2a
3.0 ± 0.0 (S)a 0.0 ± 0.0 (S)a
Table 1  Assessed cecum lesion (sum of longest diameters, mm, at mucosal site (M) and serosal site (S), means ± SD) and adhesion 
severity (score 0-7, Min/Med/Max)
At 1 min post-injury, administration of medication (/kg, 10 mL/2 min bath/rat) at the perforated (5 mm diameter) lesion and cecum, includes BPC 157 (10 
µg), NOS-blocker L-NAME (5 mg), NOS-substrate L-arginine (100 mg) alone or combined, a saline bath of equal volume (controls), and rats were left after 
abdominal closure undisturbed till the sacrifice, at day 1 or day 7. Minimum aP < 0.05 vs control.
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communication between the lumen and peritoneal cavity 
that was partly closed by a loose clot with much debris 
and many inflammatory cells (Figure 10). In treated 
animals, the defect was sealed with well-formed granu-
lation tissue. The surrounding mucosa in controls was 
edematous, and the epithelium showed practically no 
regenerative activity. However, in treated animals, the 
edema was much less pronounced, and the surface 
epithelium began to migrate over the defect.
However, no lethal outcome was noted during the 
experiment.
DISCUSSION
Major disturbances in an immediate post-injury period 
also entails the possible injury reversal in studies of 
ischemic colitis and inferior caval vein occlusion[20,21]. 
Thus, to reverse the immediate post-perforation threat 
in the cecum (and, therefore, the complete downhill 
course) we focused on the immediate post-perforation 
period. We also addressed the novel aspect of vascular 
rescue through the application of cytoprotective agents, 
known, as a class, to function in endothelium mainte-
nance in the gastrointestinal tract (and, thus, mucosal 
maintenance)[4-9]. Instant application of the stable 
gastric pentadecapeptide BPC 157 was used as a proto-
type agent rapidly acting on endothelium integrity 
maintenance[10-19], which is known to be of therapeutic 
value in rats with ischemic colitis and inferior caval vein 
ligation[20,21]. 
Of note, the whole initial syndrome (in particular, ins-
tantly emptied blood vessels at the cecum serosa and 
thus the rapid “disappearance” of existing vessels and 
failure of vessel function upon injury) and, consequently, 
perforation defect enlargement and fluid leakage, profuse 
bleeding, increased oxidative stress and disturbed NO 
levels in cecum tissue were accordingly affected. 
We suggest that this effect should be seen, based 
on evidence of BPC 157 rapidly activating the collateral 
circulation from existing vessels in rats with ischemic 
colitis[20] or inferior caval vein occlusion[21]. Thus, the 
essential findings (i.e., cecum perforation syndrome oc-
curring in BPC 157-treated rats shows attenuation and 
reversal of the consequent tissue damages) indicate the 
rapidly activated bypassing loops (i.e., through arcade 
vessels or the left ovarian vein and other veins)[20,21], 
corresponding to the prompt reperfusion seen after perfo-
ration. Reperfusion may be observed by vessels “running” 
toward the defect (vessels filled/reappeared), and a 
small-vessel network appearing around the perforated 
C B
Figure 8  Gross presentation of the area of perforation [left, control (C); right, BPC 157 (B)] and perforated injury [left, control (C)]. Presentation at day 7. 
Veho discovery VMS-004D-400x USB microscope. Control, 7 d, left, C. Gross lesion shown upon cecum opening before sacrifice. BPC 157, 7 d, mucosa presentation 
without a grossly visible defect (right, BPC 157 (B)).
BC
Figure 7  At 10 min, in the perforated cecum, the illustrative effect of medication administration [saline bath (left, control (C)] and BPC 157 bath [right, 
BPC 157 (B)]. In the damaged cecum, the regular effect of saline bath application on vessels presentation [left, control (C)] vs the immediate effect of BPC 157 bath 
administration on the blood vessels presentation toward the perforated injury [right, BPC 157 (B)].
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defect with BPC 157 bath administration. Each considered 
a break of blood flow, this suggests that the therapy 
resolving the defect (i.e., cecum defect enlargement 
reversed to defect contraction in BPC 157-treated rats) 
may be a result of the reestablishment of blood flow. 
The bleeding time from the perforated cecum is thereby 
shortened, as demonstrated in rats with amputation, 
anticoagulant application, or vein obstruction[21,42,43]. 
Furthermore, defect closing corresponds to the closing 
of various fistula defects, which were surgically made by 
particular defect creations in corresponding organs[34-38].
In addition, the free radical scavenger effect and 
normalization of NO tissue values noted in rats with 
ischemic colitis or inferior vein obstruction in colon and 
venous tissues in both ischemia and reperfusion[20,21] 
correspond to the reduction in increased MDA values 
and normalization of NO values in cecum tissue in 
perforation studies. Heavy loss of endothelium cells 
from the vascular wall and, therefore, less eNOS NO pro-
duction ability[44] would explain increased MDA values 
and decreased NO levels, which were regularly found 
in the cecum. Additionally, various free radical-induced 
lesions in other organs were counteracted by BPC 157 
administration[20,21,45-48].
The importance of these beneficial effects was 
verified by the final complete closing of the defect, 
both grossly and microscopically, with the surface epi-
thelium beginning to migrate over the defect and a 
lower adhesion severity score. It may also be that BPC 
157 exhibits an additional beneficial effect because it 
counteracts peritonitis and adhesion formation along 
with beneficial effects in diverse intestinal lesion mo-
dels[34-36,39,40].
Thus, it may be generally observed, that BPC 157 
promptly facilitates and extends the cytoprotection 
background (endothelium maintenance → epithelium 
maintenance = blood vessel recruitment and activation 
toward injury, providing also described “bypassing” of 
occlusion through alternative ways)[20,21]; thus, all chains 
of events were accordingly and promptly involved to 
rapidly initiate and achieve a full healing effect. 
This specific level of healing (initial and final) can be 
not obtained from the effect of NOS-blockade (L-NAME) 
or NOS-substrate (L-arginine), two pharmacologically 
distinct mechanisms with opposite effects on the same 
signaling NO-pathway[13]. Initially, L-arginine reduced 
vessel disappearance and counteracted defect widening, 
and prolonged the bleeding period. With L-NAME, vessel 
disappearance was similar to that in the controls; how-
ever, there was counteraction of defect widening, and 
the bleeding period was shortened. These would both 
be inadequate, though NO-specific, responses [given 
together, L-NAME+L-arginine regularly reversed each 
other’s initial responses, being not different from the 
controls, with a bleeding period similar to the controls 
(L-NAME+L-arginine)]. Namely, they both eventually 
aggravated perforated lesions in the cecum, a non-
NO-specific effect (given together, they did not reverse 
c b
C B
Figure 9  At the first day post-injury, controls (c, C) exhibited intensive edema, loss of glands in the vicinity of the perforation, not possible to obtain a 
complete defect (due to edema, the tissue is disintegrating), scarce inflammation, and neutrophils [c, HE x 4; C, HE x 10 (control)]. In rats treated with BPC 
157 (b, B), we noted much less edema and intensive inflammation (mixed-neutro and mono). Fibrin cloth attached to defect (“holding” the edges) (b, HEx4; B, HEx10 
(BPC 157)). 
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each other’s final responses: L-NAME+L-arginine rats 
still had an open defect larger than that in the controls 
with adhesions of higher score). By contrast, as a proof 
of concept regarding the beneficial effects of BPC 157, 
rats in experiments with perforated cecum and colitis 
syndromes[20] showed the counteraction of the worsening 
of the course of injury after L-NAME and L-arginine 
application as individual agents (L-NAME rats; L-arginine 
rats → L-NAME+BPC 157 rats, L-arginine+BPC 157 rats 
≈ BPC 157 rats) . When given together, the counteraction 
of the remaining extensive pathology was observed 
regardless of whether L-NAME and L-arginine reversed 
each other’s worsening responses (L-NAME + L-arginine 
rats → L-NAME + L-arginine + BPC 157 rats ≈ BPC 157 
rats)[20]. 
In conclusion, the remaining extensive pathology 
in the L-NAME+L-arginine animals (both in early and 
final terms) means that other systems (i.e., the BPC 
157 system) may function along with the NO system 
(previously supposed to be immobilized by the mutual 
actions of combined L-NAME and L-arginine)[13]. In the 
case of the effectiveness of BPC 157, the normalized 
MDA values and NO levels (always with progressive 
vessel presentation, a shortened bleeding time, closure 
of the defect, surface epithelium migration over the 
defect and fewer adhesions) indicated effectiveness over 
the background of the NO-system, whether immobilized 
(L-NAME + L-arginine), overstimulated (L-arginine) or 
blocked (L-NAME)[13]. Thus, BPC 157 could consolidate 
the NO system’s stimulating and inhibiting effects toward 
more effective healing (i.e., revascularization (vessel 
“running” toward the defect and small vessel network 
around the perforated defect) appearing with BPC 157 
bath administration)[13]. Furthermore, this additional rapid 
cytoprotective vascular recovery and presentation leads 
to a consequent strong angiogenic effect in subsequent 
days[12,18,23-27,49,50], more profound than the angiogenesis 
of standard anti-ulcer agents[50] because of its interaction 
with several molecular pathways[21-27]. Illustratively, in 
other studies, BPC 157 induced an acceleration of blood 
flow recovery and vessel number within days in rats with 
hind limb ischemia[25].
Additionally, in practice, this means distinct endpoints 
should be overwhelmed to achieve the presentation seen 
in rats that underwent BPC 157 application. Finally, in 
addition to counteracting the parallel (worsening) effect 
of L-NAME/L-arginine on ischemic colitis and cecum 
perforation syndromes[21], BPC 157 counteracts the 
common parallel L-NAME/L-arginine activity points in 
other assays (i.e., magnesium intoxication and miosis/
mydriasis)[51,52]. Notably, BPC 157 instantly prevents and 
reverses L-NAME-induced hypertension and L-NAME-
induced thrombocytopenia as well as L-arginine-induced 
hypotension and L-arginine-induced prolonged bleeding 
c b
C B
Figure 10  In control animals (c, C), the perforation after 7 d shows a communication between the lumen and peritoneal cavity, partly closed by a loose 
cloth with many debris and inflammatory cells [c, HE x 4; C, HE x 10 (control)]. In rats treated with BPC 157 (b, B), the defect was sealed with well-formed 
granulation tissue. The surrounding mucosa in controls was edematous, and the epithelium shows practically no regenerative activity, while in treated animals, the 
edema was much less pronounced and the surface epithelium started to migrate over the defect [b, HE x 4; B, HE x 10 (BPC 157)].
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and thrombocytopenia[13]. 
Therefore, BPC 157, with certain vascular effects[20,21] 
and NO-effect[13] can be used in perforated cecum and 
bleeding therapy.
ARTICLE HIGHLIGHTS
Research background
To illustrate the background, present status, and significance of the study 
we should emphasize that in cecum perforation studies the immediate 
post-perforation threat is rarely studied. On the other hand, we recently 
claimed that treatment with the prototype cytoprotective agent, stable gastric 
pentadecapeptide BPC 157, induces bypassing of occlusions in rats that 
underwent vessel occlusions through the rapid presentation of collaterals, 
and exert its free radical scavenger effect in both ischemia and reperfusion. 
As a consequence, in this study, we focused on the resolving of the cecum 
perforation lesion, particularly the rapid disappearance of blood vessels in the 
cecum serosa that are instantly emptied and thereby “disappear”, perforation 
defect enlargement, bleeding and fluid leakage, increased oxidative stress and 
disturbed NO levels in cecum tissue. 
Research motivation
The main topics, the key problems to be solved, and the significance of solving 
these problems for further research are related to reverse the immediate post-
perforation threat in the cecum (and, therefore, the complete downhill course). 
We focused on perforated cecum, the stable gastric pentadecapeptide BPC 
157, the NOS-blocker L-NAME, and the NOS-substrate L-arginine, as well as 
on the initial post-perforation period, rapid disappearance of blood vessels at 
the cecum serosa (emptied/disappeared), a large immediate defect, bleeding, 
leakage of fluid, increased oxidative stress and disturbed NO levels in 
cecum tissue. The rationale was that BPC 157 rapidly activated the collateral 
circulation from the existing vessels in rats with ischemic colitis or inferior 
caval vein occlusion. This was further perceived as an extended cytoprotection 
background (endothelium maintenance → epithelium maintenance = blood 
vessel recruitment and activation toward injury), also described as “bypassing” 
occlusion via alternative ways, as demonstrated with BPC 157, which, in 
principle, can likely cure rats with perforated cecum and thereafter.
Research objectives
The main objectives, the objectives that were realized, and the significance 
of these objectives for future research could be summarized as follows. In 
practice, as described previously, our approach to cure perforated cecum 
begins with the original understanding of stomach cytoprotection (a very rapid 
protection of the stomach endothelium and epithelium against diverse direct 
injuries; endothelium maintenance → epithelium maintenance), as “bypassing” 
occlusion via alternative ways, as demonstrated with BPC 157. Furthermore, 
we used these findings as the general argument that under analogous or 
even worse conditions (i.e., perforated cecum) a similar positive outcome can 
appear. Consequently, BPC 157 can attenuate cecum perforation syndrome; 
in BPC 157-treated rats, therapy may lead to attenuation and reversal of the 
consequent tissue damage. Especially, reversal of vessel disappearance 
to vessel “running” toward the defect (vessel filled/reappeared), reversal of 
defect enlargement to defect narrowing, reversal of prolonged bleeding to 
bleeding attenuation can induce reduction in the increased MDA values and 
normalization of NO values in cecum tissue. In subsequent days and weeks, 
this may lead to a closed cecum defect and attenuation of adhesion formation.  
Research methods
As an advantageous principle, methodology includes direct monitoring of 
the events occurring in rats during perforation of the cecum and immediately 
thereafter with the application of the stable gastric pentadecapeptide BPC 157, 
as a cytoprotective agent, and NO-agents, L-NAME and L-arginine. In deeply 
anaesthetized rats the cecum was exposed, and a perforation (5-mm diameter) 
was made at the ventral face of the basal region of the cecum close to the 
largest curvature; the rats were monitored for the next 15 min. The agents’ 
application (after 1 minute, medication (/kg, 10 mL/2min bath/rat) includes: 
BPC 157 (10 μg), L-NAME (5 mg), L-arginine (100 mg) alone or combined, 
and saline baths (controls)) on the rat perforate caecum injury. Alongside with 
the agents’ application, we continuously assessed the gross reappearance of 
the vessels (USB microcamera) quickly propagating toward the defect at the 
caecum surface, defect contraction, bleeding attenuation, MDA- and NO-levels 
in colon tissue at 15 min, and, in repalaratomized rats severity of colon lesions 
and adhesions at 1 and 7 days. 
Research results
The study of the counteraction of perforated cecum lesions in rats and the 
effects of pentadecapeptide BPC 157, L-NAME and L-arginine merits several 
emphasizes to summarize the research findings, their contribution to the 
research in the field, and the problems that remain to be solved. First, as an 
issue so far not fully addressed, to reverse the immediate post-perforation 
threat in the cecum (and, therefore, the complete downhill course) we focused 
on this immediate post-perforation period. We also addressed the novel aspect 
of vascular rescue through the application of cytoprotective agents, known, as a 
class, to function in endothelium maintenance in the gastrointestinal tract (and, 
thus, mucosal maintenance). Of note, with applied BPC 157 therapy, the whole 
initial syndrome (in particular, instantly emptied blood vessels at the cecum 
serosa (thus rapid “disappearance” of the existing vessels and vessel function 
failure upon injury)) and, consequently, perforation defect enlargement and fluid 
leakage, profuse bleeding, increased oxidative stress and disturbed NO levels 
in cecum tissue were accordingly affected. This specific level of healing (initial 
and final) can be not obtained from the effect of NOS-blockade (L-NAME) or 
NOS-substrate (L-arginine).
Research conclusions
As the new findings, we suggest that this recovering of the perforated cecum 
should be an activity much like an activity seen when BPC 157 rapidly activated 
the collateral circulation from existing vessels in rats with ischemic colitis or 
inferior caval vein occlusion. Thus, the essential findings (i.e., cecum perforation 
syndrome occurs in BPC 157-treated rats with attenuation and reversal of the 
consequent tissue damages) indicate the rapidly activated bypassing loops (i.e., 
through arcade vessels or the left ovarian vein and other veins, corresponding 
to the prompt particular vascular rescue seen after perforation). Vascular 
rescue may be vessels “running” toward the defect (vessel filled/reappeared), 
and a small-vessel network appears around the perforated defect with BPC 
157 bath administration. Each considered a break of blood flow, suggests that 
the therapy resolving the defect (i.e., cecum defect enlargement reversed to 
defect contraction in BPC 157-treated rats) may be reestablishing blood flow. 
That explanation represents the newest theoretical extension of cytoprotection 
theory background (endothelium maintenance → epithelium maintenance = 
blood vessel recruitment and activation toward injury, providing also described 
“bypassing” of occlusion through alternative ways). Since all chains of events 
could be accordingly and promptly involved to rapidly initiate and achieve a 
full healing effect. The bleeding time from the perforated cecum is thereby 
shortened, as previously demonstrated in rats with amputation, anticoagulant 
application, or vein obstruction. Furthermore, defect closing corresponds to the 
previously demonstrated closing of various fistula defects, which were surgically 
made by particular defect creations in corresponding organs. The implications 
of this study for clinical practice in the future can be that BPC 157, with certain 
vascular effects and NO-effect, can be used in the perforated cecum and 
bleeding therapy.
Research perspectives
The main experiences and lessons that can be learnt from this study may be 
the evidence that BPC 157 promptly facilitates and extends the cytoprotection 
background (endothelium maintenance → epithelium maintenance = blood 
vessel recruitment and activation toward injury, providing also described 
“bypassing” of occlusion through alternative ways). Thus, the evidence was 
obtained that all chains of events were accordingly and promptly involved to 
rapidly initiate and achieve a full healing effect, and with the respect to the 
corresponding positive effects in two other studies (ischemic/reperfusion colitis; 
inferior caval vein occlusion), the beneficial effect in rats with perforated cecum 
may be generally observed. Thereby, the future research should be related 
to the similar and/or even worse condition, to verify full significance of the 
presented beneficial findings seen in rats after cecum perforation and BPC 157 
therapy application. 
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